Equities

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

688076:SHH

Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)53.81
  • Today's Change0.03 / 0.06%
  • Shares traded3.31m
  • 1 Year change+60.96%
  • Beta1.1813
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments678406635
Total Receivables, Net341273166
Total Inventory377323251
Prepaid expenses28146.94
Other current assets, total713746
Total current assets1,4951,0521,104
Property, plant & equipment, net1,5791,054741
Goodwill, net156156161
Intangibles, net14313198
Long term investments11795--
Note receivable - long term------
Other long term assets------
Total assets3,5472,5222,127
LIABILITIES
Accounts payable18711177
Accrued expenses564235
Notes payable/short-term debt662380132
Current portion long-term debt/capital leases451.473.64
Other current liabilities, total241728
Total current liabilities973551275
Total long term debt30402.74
Total debt1,011381138
Deferred income tax10114.26
Minority interest1915(2.61)
Other liabilities, total713536
Total liabilities1,377612316
SHAREHOLDERS EQUITY
Common stock213213213
Additional paid-in capital1,3411,3191,318
Retained earnings (accumulated deficit)499378280
Treasury stock - common------
Unrealized gain (loss)(25)----
Other equity, total141----
Total equity2,1701,9101,811
Total liabilities & shareholders' equity3,5472,5222,127
Total common shares outstanding213213213
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.